🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Soleno Therapeutics executive sells over $91k in stock

Published 04/03/2024, 09:41 PM
SLNO
-

Soleno Therapeutics Inc. (NASDAQ:SLNO), a company specializing in electromedical and electrotherapeutic apparatus, reported that Senior Vice President of Regulatory Affairs, Patricia C. Hirano, sold a total of $91,693 worth of company stock. The transactions occurred on April 1, 2024, and were made public through a recent filing.

The sales were executed in multiple trades with prices ranging from $40.42 to $42.28. Specifically, Hirano sold 1,330 shares at an average price of $41.1227 and 888 shares at an average price of $41.6671. These sales were part of a plan to cover tax withholding obligations related to the vesting of restricted stock units (RSUs). Following these transactions, Hirano still owns a significant number of shares, including RSUs which represent a contingent right to receive additional shares of common stock upon vesting.

Investors often monitor insider sales as they may provide insights into an executive's perspective on the company's current valuation and future prospects. The disclosure of such sales is a routine part of corporate transparency and is required by securities regulations.

The company's stock, traded under the ticker SLNO, may experience movements following the announcement of these sales, as market participants digest the news. Soleno Therapeutics Inc. continues to operate in its sector, developing innovative solutions in the medical device field.

InvestingPro Insights

Soleno Therapeutics Inc. (NASDAQ:SLNO) has been navigating a dynamic market, evidenced by the substantial price uptick over the last six months, which has seen a 64.6% increase. This robust performance aligns with a staggering one-year price total return of 1654.62%, demonstrating a significant surge in investor confidence and market valuation for the company.

In terms of financial health, an InvestingPro Tip highlights that Soleno Therapeutics holds more cash than debt on its balance sheet, which could provide a cushion against market volatility and ensure operational resilience. Additionally, analysts predict the company will be profitable this year, a promising outlook that may influence investor sentiment and stock performance in the coming months.

However, the company's current Price / Book ratio stands at a high 8.61 as of the last twelve months ending Q4 2023. This indicates that the stock is trading at a premium compared to the company's book value, which could suggest a rich valuation or high investor expectations for future growth.

Investors considering Soleno Therapeutics as part of their portfolio can explore further InvestingPro Tips to gain deeper insights into the company's performance and potential. There are 11 additional tips available on InvestingPro, which can be accessed by visiting https://www.investing.com/pro/SLNO. To enhance your research experience, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.